Serial spot hydroxyproline/creatinine ratios in metastatic prostatic cancer

Area of Science:

• Oncology
• Biochemistry
• Urology

Background:

• Metastatic malignancies often involve bone, requiring reliable monitoring markers.
• Prostatic cancer frequently presents with predominant bone metastases, necessitating specific indicators.
• Current markers like acid and alkaline phosphatase have limitations in assessing osseous response.

Purpose of the Study:

• To evaluate urinary hydroxyproline as a marker for monitoring bone involvement in stage D2 prostatic cancer.
• To compare the efficacy of urinary hydroxyproline with bone scans and phosphatase levels in assessing treatment response.
• To determine if urinary hydroxyproline can serve as an early objective sign of osseous response.

Main Methods:

• Analysis of urinary hydroxyproline levels in 32 men with stage D2 prostatic cancer.
• Monitoring patients via bone scans, acid phosphatase, and alkaline phosphatase values.
• Serial measurements were taken 4 to 36 months post-treatment initiation (hormonal manipulation and/or chemotherapy).

Main Results:

• Urinary hydroxyproline values progressively increased in patients with disease progression (based on bone scan).
• Elevated urinary hydroxyproline was significantly higher in progressing patients compared to stable/improving patients (p < 0.001).
• Alkaline phosphatase showed less significant differences; acid phosphatase was unreliable for osseous response.

Conclusions:

• Urinary hydroxyproline is a predictive and early objective marker for osseous response in stage D2 prostatic cancer.
• This marker aids in monitoring bone metastases during treatment for advanced prostate cancer.
• Hydroxyproline levels offer a more sensitive indicator of bone involvement compared to traditional phosphatase assays.